193. Prader-Willi syndrome Clinical trials / Disease details

Clinical trials : 111 / Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03197662 (ClinicalTrials.gov)	April 11, 2018	19/6/2017	Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome	Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Prader-Willi Syndrome;Hyperphagia	Drug: Intranasal Oxytocin (IN-OXT);Drug: Matched Placebo	Montefiore Medical Center	NULL	Recruiting	5 Years	17 Years	All	50	Phase 2	United States
2	NCT03245762 (ClinicalTrials.gov)	August 1, 2017	7/8/2017	Intranasal Oxytocin for Infants With Prader-Willi Syndrome	Intranasal Oxytocin for Treatment of Infants and Children With Prader-Willi Syndrome in Nutritional Phase 1a - Phase 2 Study	Prader-Willi Syndrome	Drug: Oxytocin;Drug: Placebo	University of Florida	Prader-Willi Syndrome Association	Completed	N/A	6 Months	All	15	Phase 1/Phase 2	United States
3	NCT02629991 (ClinicalTrials.gov)	October 2015	18/10/2015	Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Prader-Willi Syndrome;Hyperphagia	Drug: Intranasal Oxytocin (IN-OXT);Drug: Matched Placebo	Montefiore Medical Center	Foundation for Prader-Willi Research	Unknown status	5 Years	18 Years	All	24	Phase 2	United States
4	NCT02013258 (ClinicalTrials.gov)	March 2015	11/12/2013	Oxytocin Trial in Prader-Willi Syndrome	Oxytocin Trial in Prader-Willi Syndrome	Prader Willi Syndrome	Drug: Intranasal oxytocin;Other: Placebo	University of Florida	National Institutes of Health (NIH)	Completed	5 Years	11 Years	All	24	Phase 1	United States
5	EUCTR2021-000094-91-FR (EUCTR)		01/04/2021	EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA IN CHILDREN AND ADOLESCENTS WITH PRADER WILLI SYNDROME	EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA RELATED TO OROPHARYNGO-OESOPHAGEAL DYSMOTILITY TRANSIT IN CHILDREN AND ADOLESCENTS WITH PRADER-WILLI SYNDROME: A PHASE 3 STUDY (DYSMOT) - DYSMOT	Prader-Willi Syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: OXYTOCIN Product Code: H01BB02	Toulouse University Hospital	NULL	NA			Female: yes Male: yes	36	Phase 3	France